THE DOSE The peptide market decoded — science, signal, and BS detection for the biohacking era. Monday, March 16, 2026

COMPOUND WATCH

Tirzepatide (compounded + B12) — [Flagged | Unknown reaction impurity | Recall demand issued] Semaglutide (Wegovy 2.4mg injectable) — [Phase 3 | 5x ION risk vs. other semaglutide formulations] Semaglutide (Rybelsus oral) — [Phase 3 | Zero ION reports — meaningful safety differentiation] BPC-157 — [Animal | Zero published human RCTs | First Phase 2 now recruiting: NCT07437547] Retatrutide — [Phase 3 recruiting | 28.7% mean weight loss at 48 weeks, Phase 2] Orforglipron — [Phase 3 complete | FDA approval expected Q2 2026 | Small molecule — cannot be compounded]

Two safety signals and one supply-chain development dropped this week that affect decisions you may be making today.

Signal 1: Tirzepatide + B12 impurity. Eli Lilly issued a formal public warning letter to the FDA identifying an unknown chemical impurity produced by a reaction between tirzepatide and vitamin B12 — all three forms: methylcobalamin, hydroxocobalamin, and cyanocobalamin. Lilly called for recalls of affected compounded products and separately flagged bacterial contamination, elevated endotoxin levels, and additional impurities across compounded tirzepatide broadly. Full details via Pharmacally.

Check your current vial right now. Many compounders added B12 to reduce injection site discomfort — that formulation is now subject to a formal recall demand. A clean COA on the tirzepatide API doesn't tell you what happens when it reacts with methylcobalamin in the same vial. The impurity is uncharacterized: nobody knows what it does. Until your compounder provides independent testing on the combined formulation — not just the API — treat any tirzepatide + B12 combination as [Flagged].

Signal 2: Wegovy ION risk. A new study in the British Journal of Ophthalmology analyzed FAERS data (December 2017–December 2024, ~32,000 semaglutide reports) and found Wegovy users have approximately 5x higher risk of ischemic optic neuropathy (ION) versus other semaglutide-based GLP-1s. Risk is roughly 3x higher in men than women. Working hypothesis: Wegovy's higher dose (2.4mg vs. Ozempic's 2.0mg) is the driver. Critically: zero ION reports were associated with Rybelsus (oral semaglutide). FAERS isn't an RCT — but a 5x differential across 32,000 reports over 7 years is not noise. If you're male, on Wegovy, and have any vascular risk factors, bring this to your prescriber. ION causes sudden, permanent vision loss.

GLP-1 discontinuation reality check. A Cleveland Clinic real-world study (n=7,938, Diabetes, Obesity and Metabolism) found more modest weight regain after GLP-1 discontinuation than prior RCTs suggested. In the obesity cohort, 55% gained weight post-discontinuation — but 45% maintained or continued losing. Important caveat: "maintained or continued losing" likely includes people who restarted or switched therapies — the study notes many did. The 45% figure is less reassuring if it's partly a restart rate, not a sustained-off-drug effect. Prior RCT data suggested >50% weight regain within 12 months; this real-world data softens that narrative, but the mechanism hasn't changed.

VENDOR SIGNAL

No new Finnrick rating changes, failed HPLC results, or Janoshik test data surfaced today. Check finnrick.com directly before your next order — the 15–20% COA discrepancy rate across gray-market vendors is the baseline you're working against.

Compounded tirzepatide + B12 [Flagged]: Lilly's recall demand applies to any compounder shipping tirzepatide combined with B12 additives. This is a formulation chemistry problem, not a vendor legitimacy problem. A reputable compounder with a clean COA on the tirzepatide API still has an unknown impurity problem if B12 is in the same vial. Ask your pharmacy directly: Has your tirzepatide + B12 formulation been independently tested for reaction byproducts — not just the API? If they can't answer that question specifically, switch to plain tirzepatide.

IRON Peptides [COA Only]: A March 13 press release promoted their purity standards with useful math: a 90% pure peptide delivers 50mcg of unknown impurities per 500mcg dose. At 95% purity, that's 25mcg. At typical BPC-157 doses of 250–500mcg/day, the delta between 90% and 95% purity is 12.5–25mcg of unknowns injected daily. That number is worth holding when you're comparing COAs. The math is real — but this is marketing content, not independent test data. [COA Only] framing applies.

Finnrick mainstream visibility: PBS/PolitiFact (March 14) named Finnrick explicitly as "a Texas lab that provides free testing of online peptide retailers" that has found label discrepancies. Background context, not a new test result — but signals Finnrick is getting mainstream visibility, which typically precedes a surge in vendor submissions. Check the site directly for current rankings.

The B12 impurity story is the most important sourcing development in months. It's not about whether your compounder is reputable — it's about whether a chemical reaction in the vial is creating something nobody tested for.

TRIAL TRACKER

BPC-157 — First Phase 2 Human Trial [Phase 2 | Recruiting] NCT07437547: "BPC-157 for Acute Hamstring Muscle Strain Repair." Started February 2, 2026. Verify enrollment status directly on ClinicalTrials.gov. This is the single most important development in the BPC-157 space in years — the compound has zero published human RCTs despite being injected by hundreds of thousands of people. This trial doesn't validate BPC-157; it begins the process of finding out whether it does anything in humans. Preliminary results are likely 18–24 months out.

Retatrutide — Phase 3 Obesity [Phase 3 | Recruiting] NCT07357415 (started January 2026) is enrolling non-diabetic obese/overweight participants. A separate maintenance study (NCT06859268) is active but not recruiting. Retatrutide posted 28.7% mean weight loss at 48 weeks in the Phase 2 TRIUMPH trial — the highest of any GLP-1-class compound in a controlled trial to date. Phase 3 will determine whether that number holds in a broader population. Clarivate projects it as a major obesity market driver post-2028. This is the compound most likely to reshape the GLP-1 compounding landscape in 3–4 years.

Semaglutide Nasal Spray — Phase 1 [Phase 1 | Recruiting] NCT07465965: Started March 2, 2026. First clinical study of intranasal semaglutide in overweight/obese adults. Very early — Phase 1 safety/dosing only. Context from today's ION data makes this worth watching: if injectable semaglutide's dose is driving the vision risk signal, and oral Rybelsus showed zero ION reports, nasal delivery bioavailability data will matter.

THE ODDS

China invasion odds: 11% probability ($11.1M volume traded) The most-traded signal in this market today — and the most relevant supply chain risk for gray-market peptide buyers. At 11%, it's not a planning scenario. But any escalation in US-China trade tension raises the cost of gray-market peptides 15–30% via tariff pass-through. The $2–5 Chinese factory price for BPC-157 API becomes $2.30–$6.50 under a 15–25% tariff. That's still cheap — but it compresses vendor margins and increases the incentive to cut corners on purity. The tariff dividend odds (3%, $136K volume) confirm the market isn't pricing in near-term trade relief. If you're sourcing from QSC/SRY-type vendors, the supply chain risk isn't rates — it's geopolitics.

Inflation above 3% in 2026: 94% probability ($128,561 volume traded) As close to a certainty as prediction markets produce. What it means practically: compounding pharmacy costs are already running $200–500/month for tirzepatide. A rough estimate based on typical 503A cost structure — 60–70% labor, remainder API and overhead — suggests 3–4% CPI translates to 5–8% input cost inflation at the pharmacy level; add API and shipping, and 8–12% total price increases over the next 90 days is a plausible working estimate, not a sourced figure. If your compounder raises prices in that range, that's inflation materializing, not gouging. Budget for it or lock in longer supply runs at current pricing.

US Recession by end of 2026: 30% probability ($626,389 volume traded) Below the threshold where sourcing behavior shifts dramatically. Working hypothesis — not validated by a prior cycle — is that recession probability above 40% shifts price-sensitive buyers toward gray-market vendors as they trade down from compounders. Watch the trend, not just the number. A 10-point move up changes the calculus.

SIGNAL VS. NOISE

SIGNAL: Tirzepatide + B12 impurity warning [Flagged] Lilly's formal letter to the FDA is a legal and regulatory document calling for recalls — not a press release. The impurity is uncharacterized. This affects a large percentage of compounded tirzepatide currently in circulation. Actionable today: contact your compounder, ask specifically whether the combined tirzepatide + B12 formulation has been independently tested for reaction byproducts. Silence is a [Flagged] signal.

SIGNAL: Wegovy ION risk — 5x vs. other semaglutide formulations FAERS isn't an RCT, but 32,000 reports over 7 years with a 5x differential and a mechanistically coherent dose-dependent hypothesis is a real signal. The zero-ION finding from oral Rybelsus is meaningful safety differentiation. If you're male, on Wegovy, with any vascular risk factors — bring this to your prescriber before your next refill.

SIGNAL: Samsung BioEpis / G2GBIO long-acting semaglutide deal (today) Samsung BioEpis signed a deal with G2GBIO today for microsphere-based long-acting semaglutide and one additional obesity candidate. Deal value undisclosed but exceeds 10% of G2GBIO's 2024 revenue (~770M KRW); Samsung Epis Holdings is also investing 20B KRW in G2GBIO convertible bonds. This is a 2–3 year signal, not a today signal — but it confirms the Asian biosimilar/long-acting GLP-1 pipeline is moving. Long-acting semaglutide formulations that reduce injection frequency will reshape the compounding landscape when they arrive.

SIGNAL: BPC-157 Phase 2 trial recruiting NCT07437547 is the first human RCT for BPC-157. It doesn't validate the compound — it begins the evidentiary process. For the community injecting this daily, it's the most important development in years.

NOISE: RFK Jr. "war on peptides" rhetoric RFK promised to end the "war on peptides" in a February 27 Joe Rogan interview. PBS/PolitiFact covered it March 14 and made the obvious point: RFK demands RCTs for vaccines but not for peptides he personally uses. More importantly — no formal FDA rule has been issued. No Federal Register notice. No Category 1/2 reclassification. Enforcement discretion only. Do not make sourcing decisions based on RFK's podcast comments. Treat any vendor claiming "RFK legalized peptides" as [Flagged].

NOISE: The "Wolverine stack" mainstream media coverage Both PBS and The Times named the BPC-157 + TB-500 stack explicitly this week. When a biohacking stack gets named in The Times' lifestyle section, you're at the top of the hype cycle, not the beginning of validated science. Evidence grade for both: [Animal]. TB-500 has no human RCTs. BPC-157 now has one Phase 2 recruiting. WADA bans both. The mainstream coverage doesn't change the evidence — it tells you demand is about to spike and vendor quality pressure is about to increase.

REGULATORY RADAR

Compounded tirzepatide enforcement is tightening. Per Pharmacally's characterization of recent FDA activity, the agency has stepped up enforcement actions against the mass distribution of compounded tirzepatide. Lilly's B12 impurity letter is the second major enforcement-adjacent move in weeks. Novo Nordisk has separately criticized telehealth platforms distributing compounded versions of its therapies, in ongoing tension with Hims & Hers.

FDA Warning Letter — Novo Nordisk: A TrialSite News piece (March 14) references an FDA Warning Letter hitting Novo Nordisk with a headline suggesting a secondary enforcement action beyond the Ozempic headline — content is paywalled and we couldn't verify specifics. If you have TrialSite access, pull it. We'll follow up when details surface. Do not act on the headline alone.

Orforglipron — Q2 2026 approval watch. Lilly's oral, non-peptide GLP-1 receptor agonist is the first oral, non-peptide GLP-1 to reach Phase 3, and FDA approval is expected Q2 2026. Lilly has pre-built a $1.5 billion stockpile of pills and filed with Chinese regulators alongside a $3 billion decade-long China manufacturing commitment. Critical distinction: orforglipron is a small molecule — it cannot be compounded under the frameworks that apply to semaglutide and tirzepatide. Its approval doesn't directly affect the compounding market, but a once-daily oral GLP-1 at competitive pricing changes the calculus for patients currently on compounded injectables.

Kroger + Zepbound KwikPen access expansion. Zepbound KwikPen is now available at participating Kroger retail pharmacies for self-pay patients, with Lilly's KwikPen Self-Pay Savings Card honored. No specific price was listed in the Kroger announcement. For context: Zepbound's list price runs approximately $550/month; Lilly's Self-Pay Savings Card has historically reduced this to approximately $349/month for eligible patients — treat that figure as approximate and verify with your pharmacy. Compounded tirzepatide runs $200–500/month depending on compounder and dose. The Kroger expansion narrows the access gap but doesn't close the price gap — yet. Watch for Lilly to adjust savings card terms as orforglipron approaches approval.

Sana Biotechnology — first-in-human milestone (not our core beat, but worth knowing). Sana Biotechnology (SANA, +8.74% on March 14) reported 14-month survival of HIP-modified islet cells in a single T1D patient without immunosuppression — C-peptide levels detectable and comparable to months 1–6. This is C-peptide/islet cell territory, not a peptide supplement story. But it's a first-in-human milestone with a meaningful stock move in the peptide therapeutics space. IND for SC451 (stem cell-derived HIP islet therapy) expected to be filed with Phase 1 initiated as early as 2026.

RFK reclassification: still rhetoric, not rule. No Federal Register notices reclassifying BPC-157, TB-500, CJC-1295, Ipamorelin, or GHK-Cu from Category 2 to Category 1 have been issued. Enforcement discretion is not a legal protection. Your 503A compounder's legal exposure has not changed.

WHAT TO WATCH

Today (March 16): Check your current tirzepatide formulation for B12 content. If it contains any form of B12 (methylcobalamin, hydroxocobalamin, cyanocobalamin), contact your compounder and ask this specific question: Has your tirzepatide + B12 combined formulation been independently tested for reaction byproducts — not just the tirzepatide API? A COA on the API alone does not answer this question.

This week — compounder response monitoring: Compounders who proactively reformulate or provide independent testing data on the combined formulation are demonstrating quality controls. Silence or a generic "our products are safe" response is a [Flagged] signal. Switch to plain tirzepatide if you can't get a specific answer.

Q2 2026 — Orforglipron FDA approval: If approved, watch for self-pay pricing. A once-daily oral GLP-1 at or below $349/month (the approximate Zepbound savings card benchmark) changes the compounding calculus significantly for patients who currently use compounded injectables for cost reasons.

18–24 months — BPC-157 Phase 2 data: NCT07437547 preliminary results. Verify current enrollment status at ClinicalTrials.gov. This is the first real human signal on a compound hundreds of thousands are already injecting. It won't answer everything — but it's the first data point that isn't a rat.

Ongoing — recession odds at Polymarket: Currently 30%. Working hypothesis: if they cross 40%, gray-market sourcing behavior shifts — more QSC/SRY orders, fewer compounder orders, as price-sensitive buyers trade down. Treat this as a hypothesis to watch, not an established historical pattern. A 10-point move up changes the sourcing calculus.

The number that matters most this week: The unknown impurity in tirzepatide + B12. Not because it's proven dangerous — but because nobody knows what it is yet. That uncertainty is the risk.

Gaps acknowledged: No fresh Finnrick rating data, no Janoshik test results, no specific compounder pricing data (Empower, Olympia, Marek, Defy) surfaced today. No QSC/SRY/GYC operational status updates available. The core weekly sourcing decision — gray-market vendor vs. waiting for your compounder to restock — is partially unaddressed because no fresh independent test data exists today. Check finnrick.com directly before your next order. I won't fill data gaps with invented numbers.

Reply to this email with feedback — sourcing intelligence, test results you've run, compounder responses to the B12 warning. The signal improves when it flows both ways.

Stay curious, stay skeptical. — The Dose

Like what you're reading? Upgrade to Premium for early-access signals, weekly deep-dives, and the full 12-month archive. Founding members: $15/month. Manage your subscription.